Related Experiment Video
Updated: May 17, 2026
07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Guillain-Barré syndrome
Ximena Arcila-Londono1, Richard A Lewis
1Henry Ford Health System Department of Neurology, Detroit, MI, USA. xarcila1@hfhs.org
Seminars in Neurology
|November 3, 2012
Summary
Guillain-Barré syndrome (GBS) encompasses typical and variant forms, including acute inflammatory demyelinating polyneuropathy and axonal neuropathies. This review details their clinical features, pathology, pathogenesis, and treatment for better understanding and management.
Area of Science:
- Neurology
- Immunology
Background:
- Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy with diverse presentations.
- Common forms include acute inflammatory demyelinating polyneuropathy (AIDP) and axonal variants (AMAN, AMSAN).
- Variant syndromes like Miller Fisher and pandysautonomia present distinct clinical features.
Purpose of the Study:
- To review typical GBS and variant syndromes.
- Focus on clinical, diagnostic, pathological, and pathogenetic aspects.
- To discuss current treatment strategies.
Main Methods:
- Literature review of GBS and related neuropathies.
- Analysis of clinical presentations and diagnostic criteria.
- Synthesis of pathological and pathogenetic findings.
Main Results:
- GBS presents as demyelinating or axonal forms.
- Variant syndromes exhibit unique clinical phenotypes.
- Understanding pathogenesis aids in targeted treatment.
Conclusions:
- GBS is a spectrum of inflammatory polyneuropathies.
- Distinguishing typical and variant forms is crucial for diagnosis.
- Comprehensive management requires knowledge of underlying mechanisms and tailored therapies.
More Related Videos
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:25Secondary Spinal Cord Injury llI: Pathophysiology
Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...